Clinical Trials

Inclusion Criteria:

- Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

- At least one measurable and injectable lesion

- Have provided a former tumor pathology specimen or be willing to supply a new tumor
sample from a biopsy

- Have a predicted life expectancy of ≥ 3 months

- Measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST)
v1.1 criteria

- Subjects with MSI-H or dMMR tumors: has diagnosis of MSI-H or metatstatic dMMR tumor
(according to protocol definition) for whom anti PD-1 therapy is indicated, or have
refused, become intolerant to or have no further therapy options available

- Subjects with NMSC: has diagnosis of locally advanced or metastatic NMSC that are not
considered treatable by surgery including basal cell carcinoma, cutaneous squamous
cell carcinoma, basosquamous carcinoma, Merkel cell carcinoma and other non-melanoma
skin cancers (per protocol) for whom anti-PD1/PD-L1 therapy is indicated, or have
refused, become intolerant to or have no further therapy options available

- Subjects with anti-PD1 failed cutaneous melanoma: has confirmed progressive disease
while on anti-PD1 treatment for at least 8 weeks and documented BRAF mutation status

- Subjects with anti-PD1 failed NSCLC: has confirmed progressive disease after no more
than two prior systemic treatments including anti-PD1/PD-L1 treatment

Exclusion Criteria:

- Prior treatment with an oncolytic therapy

- History of viral infections according to the protocol

- Prior complications with herpes infections

- Chronic use of anti-virals

- Uncontrolled/untreated brain metastasis

- History of interstitial lung disease

- History of non-infectious pneumonitis

- History of clinically significant cardiovascular disease